News | February 27, 2025
Zydus Lifesciences to launch protection against new strain of influenza virus
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024
The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
EBITDA margins expand to 31.3%
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
Subscribe To Our Newsletter & Stay Updated
